Publications

Hematopoietic stem cell heterogeneity and age-associated platelet bias are evolutionarily conserved.

Aksöz M. et al, (2024), Sci Immunol, 9

Lead optimisation of OXS007417: in vivo PK profile and hERG liability modulation to optimise a small molecule differentiation agent for the potential treatment of acute myeloid leukaemia.

Cogswell TJ. et al, (2024), RSC Med Chem

Selective advantage of mutant stem cells in human clonal hematopoiesis is associated with attenuated response to inflammation and aging.

Jakobsen NA. et al, (2024), Cell Stem Cell

Somatic gene mutation patterns and burden influence outcomes with enasidenib in relapsed/refractory IDH2-mutated AML

Risueño A. et al, (2024), Leukemia Research, 140

Real-world Effectiveness of Azacitidine in Treatment-Naive Patients With Higher-risk Myelodysplastic Syndromes.

Rajakumaraswamy N. et al, (2023), Clin Lymphoma Myeloma Leuk

Changing treatment changing prognosis of mutations

Vyas P., (2023), Blood, 142, 1583 - 1585

A protocol for simultaneous high-sensitivity genotyping and chromatin accessibility profiling in single cells.

Turkalj S. et al, (2023), STAR Protoc, 4

Selective advantage of mutant stem cells in clonal hematopoiesis occurs by attenuating the deleterious effects of inflammation and aging

Jakobsen NA. et al, (2023)

Tolerability and Efficacy of the Anticluster of Differentiation 47 Antibody Magrolimab Combined With Azacitidine in Patients With Previously Untreated AML: Phase Ib Results.

Daver NG. et al, (2023), J Clin Oncol

Dysregulation of chromatin via H3K27 methylation underpins differentiation arrest in Isocitrate dehydrogenase-mutant Acute Myeloid Leukaemia

Silveira DRA. et al, (2023)

Fractionated Versus Single Dose Gemtuzumab Ozogamicin with Determinants of Benefit in Older AML: UK NCRI AML18 Trial.

Freeman SD. et al, (2023), Blood

Data from A Phase Ib/II Study of Ivosidenib with Venetoclax ± Azacitidine in IDH1-Mutated Myeloid Malignancies

Lachowiez CA. et al, (2023)

Supplementary Protocol from A Phase Ib/II Study of Ivosidenib with Venetoclax ± Azacitidine in IDH1-Mutated Myeloid Malignancies

Lachowiez CA. et al, (2023)

Supplementary Protocol from A Phase Ib/II Study of Ivosidenib with Venetoclax ± Azacitidine in IDH1-Mutated Myeloid Malignancies

Lachowiez CA. et al, (2023)

Supplementary Tables and Figures from A Phase Ib/II Study of Ivosidenib with Venetoclax ± Azacitidine in IDH1-Mutated Myeloid Malignancies

Lachowiez CA. et al, (2023)

Supplementary Tables and Figures from A Phase Ib/II Study of Ivosidenib with Venetoclax ± Azacitidine in IDH1-Mutated Myeloid Malignancies

Lachowiez CA. et al, (2023)

An Overview of Targeted Therapies in Acute Myeloid Leukemia

Turkalj S. et al, (2023), HemaSphere, 7

Data from A Phase Ib/II Study of Ivosidenib with Venetoclax ± Azacitidine in IDH1-Mutated Myeloid Malignancies

Lachowiez CA. et al, (2023)

Supplementary Protocol from A Phase Ib/II Study of Ivosidenib with Venetoclax ± Azacitidine in IDH1-Mutated Myeloid Malignancies

Lachowiez CA. et al, (2023)

Supplementary Protocol from A Phase Ib/II Study of Ivosidenib with Venetoclax ± Azacitidine in IDH1-Mutated Myeloid Malignancies

Lachowiez CA. et al, (2023)

Publications

Hematopoietic stem cell heterogeneity and age-associated platelet bias are evolutionarily conserved.

Lead optimisation of OXS007417: in vivo PK profile and hERG liability modulation to optimise a small molecule differentiation agent for the potential treatment of acute myeloid leukaemia.

Selective advantage of mutant stem cells in human clonal hematopoiesis is associated with attenuated response to inflammation and aging.

Somatic gene mutation patterns and burden influence outcomes with enasidenib in relapsed/refractory IDH2-mutated AML

Real-world Effectiveness of Azacitidine in Treatment-Naive Patients With Higher-risk Myelodysplastic Syndromes.

Changing treatment changing prognosis of mutations

A protocol for simultaneous high-sensitivity genotyping and chromatin accessibility profiling in single cells.

Selective advantage of mutant stem cells in clonal hematopoiesis occurs by attenuating the deleterious effects of inflammation and aging

Tolerability and Efficacy of the Anticluster of Differentiation 47 Antibody Magrolimab Combined With Azacitidine in Patients With Previously Untreated AML: Phase Ib Results.

Dysregulation of chromatin via H3K27 methylation underpins differentiation arrest in Isocitrate dehydrogenase-mutant Acute Myeloid Leukaemia

Fractionated Versus Single Dose Gemtuzumab Ozogamicin with Determinants of Benefit in Older AML: UK NCRI AML18 Trial.

Data from A Phase Ib/II Study of Ivosidenib with Venetoclax ± Azacitidine in <i>IDH1</i>-Mutated Myeloid Malignancies

Supplementary Protocol from A Phase Ib/II Study of Ivosidenib with Venetoclax ± Azacitidine in <i>IDH1</i>-Mutated Myeloid Malignancies

Supplementary Protocol from A Phase Ib/II Study of Ivosidenib with Venetoclax ± Azacitidine in <i>IDH1</i>-Mutated Myeloid Malignancies

Supplementary Tables and Figures from A Phase Ib/II Study of Ivosidenib with Venetoclax ± Azacitidine in <i>IDH1</i>-Mutated Myeloid Malignancies

Supplementary Tables and Figures from A Phase Ib/II Study of Ivosidenib with Venetoclax ± Azacitidine in <i>IDH1</i>-Mutated Myeloid Malignancies

An Overview of Targeted Therapies in Acute Myeloid Leukemia

Data from A Phase Ib/II Study of Ivosidenib with Venetoclax ± Azacitidine in <i>IDH1</i>-Mutated Myeloid Malignancies

Supplementary Protocol from A Phase Ib/II Study of Ivosidenib with Venetoclax ± Azacitidine in <i>IDH1</i>-Mutated Myeloid Malignancies

Supplementary Protocol from A Phase Ib/II Study of Ivosidenib with Venetoclax ± Azacitidine in <i>IDH1</i>-Mutated Myeloid Malignancies

Cookies on this website

Publications